Overview

AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC

Status:
Not yet recruiting
Trial end date:
2025-01-20
Target enrollment:
Participant gender:
Summary
AK112, alone or in combination with chemotherapy for the neoadjuvant/adjuvant treatment of resectable NSCLC
Phase:
Phase 2
Details
Lead Sponsor:
Akeso
Treatments:
Carboplatin
Paclitaxel